Table 2.
Patients' characteristics according to pCXCR4/CXCR4 TIC ratio in primary biopsies in the overall cohorta
| pCXCR4/CXCR4high | pCXCR4/CXCR4low | p-value | |
|---|---|---|---|
| n=18 (100%) | n=18 (100%) | ||
| Age (median, range) | 61.5 (47-73) | 58 (34-69) | 0.350 |
| FIGO stage | |||
| IIIB | 4 (22.2) | 0 (0) | |
| IIIC | 11 (61.1) | 15 (83.3) | 0.149 |
| IV | 3 (16.7) | 3 (16.7) | |
| Residual disease | |||
| None | 6 (33.3) | 5 (27.8) | |
| <2cm | 5 (27.8) | 9 (50.0) | 0.277 |
| >2cm | 7 (38.9) | 3 (16.7) | |
| Numbers of chemotherapy cycles | |||
| <6 | 2 (11.1) | 3 (16.7) | 0.581 |
| 6 or more | 16 (88.9) | 14 (77.8) | |
| 6-month recurrent free survival % (95%CI)b | 0.73 (0.40-0.91) | 0.47 (0.22-0.70) | 0.128 |
| 3-year overall survival % (95%CI)b | 0.30 (0.07-0.58) | 0.36 (0.13-0.59) | 0.619 |
a Cut-off = 0.1875, n = 36. Percentages may not add to 100% due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kaplan-Meier method. FIGO stage, residual disease and numbers of chemotherapy cycles were analyzed using the Chi-Square or the Fisher’s Exact test.
bRFS recurrence-free survival, OS overall survival